Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Antil L[original query] |
---|
Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt
Ortega O , El-Sayed N , Sanders JW , Abd-Rabou Z , Antil L , Bresee J , Mansour A , Adib I , Nahkla I , Riddle MS . J Infect Dis 2009 200 Suppl 1 S92-8 BACKGROUND: The availability of rotavirus vaccines makes the implementation of a national immunization program an important decision requiring economic considerations. METHODS: A cost-benefit analysis of a national rotavirus immunization program in Egypt, from the perspective of the Ministry of Health and Population, and a cost-effectiveness analysis, from a societal perspective, were conducted. RESULTS: For a birth cohort of 1.9 million children, a vaccination program was estimated to prevent 1,140,496 episodes of diarrhea, 438,395 outpatient visits, and 47,508 hospitalizations and to save 2873 lives, resulting in direct Ministry of Health and Population medical savings of $2,481,792 (14,369,578 Egyptian pounds [LE]). On the basis of a $9.18 (53 LE) single-dose cost, rotavirus vaccine introduction would cost the Ministry of Health and Population $34,203,445.87 (198,037,951.56 LE) in health expenditures. This equates to an incremental cost of $30.22 (174.95 LE) per infection prevented. Vaccination would prevent the loss of 94,993 disability-adjusted life-years, resulting in an incremental cost-effectiveness ratio of $363 per disability-adjusted life-year. CONCLUSIONS: The introduction of rotavirus vaccine to the national immunization program was not found to be cost saving based strictly from the Ministry of Health and Population perspective; however, the potential benefits of long-term health and economic gains from reduced mortality and morbidity, decreased direct costs of care for families, and indirect societal costs should be considered in such decisions. |
Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries
Rheingans RD , Antil L , Dreibelbis R , Podewils LJ , Bresee JS , Parashar UD . J Infect Dis 2009 200 Suppl 1 S16-27 BACKGROUND: Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evaluated the economic burden of rotavirus and the cost-effectiveness of vaccination from the health care perspective. METHODS: Estimates were based on existing epidemiological data, cost estimates, vaccine coverage, and efficacy data, as well as hypothetical vaccine prices. Outcome measures included health care and societal costs of rotavirus and benefits and incremental cost-effectiveness ratio of vaccination. Sensitivity analyses evaluated the impact of estimate uncertainty. RESULTS: Treatment costs increased with income level, and health burden decreased; however, burden varied across regions. On the basis of current vaccination coverage and timing, rotavirus vaccination would annually prevent 228,000 deaths, 13.7 million hospital visits, and 8.7 million disability-adjusted life-years, saving $188 million in treatment costs and $243 million in societal costs. At $5 per dose, the incremental cost-effectiveness ratio in low-, lower-middle-, and upper-middle-income countries was $88, $291, and $329 per disability-adjusted life-year averted, respectively, and $3,015, $9,951 and $11,296 per life saved, respectively. Vaccination would prevent approximately 45% of deaths and approximately 58% of associated medical visits and costs. CONCLUSIONS: Vaccination is a cost-effective strategy to reduce the health and economic burden of rotavirus. The cost-effectiveness of vaccination depends mostly on vaccine price and reaching children at highest risk of mortality. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure